颞肌厚度作为动脉瘤性蛛网膜下腔出血后可行的肌少症标志物与结局预测指标
该回顾性研究纳入2003年1月至2016年6月连续治疗的945例动脉瘤性蛛网膜下腔出血患者,利用初始CT计算平均颞肌厚度(TMT),分析其与6个月不良结局(改良Rankin量表>3)、血管造影血管痉挛、颅内高压(>20mmHg)、院内死亡及脑梗死的关系。多变量分析显示,平均TMT每增加1mm,院内死亡(aOR 0.86,95%CI 0.75-0.99)、6个月不良结局(aOR 0.86,95%CI 0.76-0.98)和血管造影血管痉挛(aOR 0.87,95%CI 0.78-0.97)风险降低,而颅内高压风险升高(aOR 1.17,95%CI 1.06-1.29)。作者认为TMT与临床病程及结局显著相关,但需在不同患者人群中进一步研究验证其临床相关性和预后价值。
要点
- 平均颞肌厚度每增加1mm,6个月不良结局风险降低(aOR 0.86,95%CI 0.76-0.98)。
- 平均颞肌厚度每增加1mm,院内死亡风险降低(aOR 0.86,95%CI 0.75-0.99)。
- 平均颞肌厚度每增加1mm,颅内高压风险升高(aOR 1.17,95%CI 1.06-1.29)。
核心结论
- 本研究发现平均颞肌厚度与动脉瘤性蛛网膜下腔出血患者的临床病程及结局存在显著相关性。
- 作者指出需在不同患者人群中进一步研究以验证TMT对该人群的临床相关性和预后价值。
研究设计与样本
- 回顾性研究,使用2003年1月至2016年6月连续治疗的动脉瘤性蛛网膜下腔出血病例数据库。
- 利用初始计算机断层扫描(CT)检查计算平均颞肌厚度(TMT)值。
- 最终队列共945例,平均TMT值为7.49mm±1.68mm。
- 主要终点为6个月时不良结局,定义为改良Rankin量表>3。
- 次要终点包括动脉瘤性蛛网膜下腔出血期间血管造影血管痉挛和颅内高压(>20mmHg)的发生、院内死亡及脑梗死形成。
主要发现
- 基线特征中,年龄(p<0.0001)、性别(p<0.0001)、肥胖(p=0.001)、甲状腺功能减退(p=0.001)和高尿酸血症(p=0.026)与平均TMT值存在显著关联。
- 最终多变量分析中,院内死亡与平均TMT独立相关(p=0.035,每毫米增加aOR 0.86,95%CI 0.75-0.99)。
- 6个月不良结局与平均TMT独立相关(p=0.018,aOR 0.86,95%CI 0.76-0.98)。
- 颅内高压与平均TMT独立相关(p=0.002,aOR 1.17,95%CI 1.06-1.29)。
- 血管造影血管痉挛的发生与平均TMT独立相关(p=0.011,aOR 0.87,95%CI 0.78-0.97)。
关键数值与推荐
- 主要终点不良结局定义为6个月时改良Rankin量表>3。
- 次要终点颅内高压定义为>20mmHg。
临床怎么用
- 原文未据此给出推荐。
局限性
- 作者指出需在不同患者人群中进一步研究以验证TMT对动脉瘤性蛛网膜下腔出血患者的临床相关性和预后价值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Sarcopenia has already been investigated as a prognostic marker for many different cancerous and non-cancerous diseases to prognosticate the clinical course. While being a sarcopenia marker, temporal muscle thickness (TMT) has gained increasing interest in recent years as a potential outcome predictor. The aim of this retrospective study was to investigate the association between TMT and the neurological outcome of patients with aneurysmal subarachnoid hemorrhage (aSAH). METHODS: A retrospective database consisting of consecutive aSAH cases treated from 01/2003 to 06/2016 was used. The initial computed tomography examinations were used to calculate the mean TMT values. Our primary endpoint was unfavorable outcome at 6 months defined as modified Rankin Scale > 3. Secondary endpoints included the occurrence of angiographic vasospasm and intracranial hypertension (> 20mmHg) during aSAH, in-hospital mortality and development of cerebral infarcts. Univariable analyses were conducted and multivariable analyses were performed on significant findings. RESULTS: The mean TMT value of the final cohort (n = 945) was 7.49mm ± 1.68mm. Of the baseline characteristics, a significant relationship with TMT mean value was found for age (p < 0.0001), sex (p < 0.0001), obesity (p = 0.001), hypothyroidism (p = 0.001), and hyperuricemia (p = 0.026). In the final multivariable analysis, the following study endpoints were independently associated with mTMT: in-hospital mortality (p = 0.035, adjusted odds ratio [aOR] 0.86 per-mm-increase, 95% confidence interval [CI] 0.75-0.99), unfavorable outcome at 6 months (p = 0.018, aOR 0.86, 95% CI 0.76-0.98), intracranial hypertension (p = 0.002, aOR 1.17, 95% CI 1.06-1.29) and the occurrence of angiographic vasospasm (p = 0.011, aOR 0.87, 95% CI 0.78-0.97). CONCLUSIONS: In this study, we found significant correlations between mTMT and the clinical course and outcome of patients with aSAH. Further studies in different patient populations are needed to validate the clinical relevance and prognostic value of TMT for aSAH patients.
引用
- Mohajerani E, Gümüs M, Dinger TF, et al. Temporal muscle thickness as a feasible sarcopenia marker and outcome predictor after aneurysmal subarachnoid hemorrhage. Acta Neurochir (Wien). 2025. PMID: 40439824. doi:10.1007/s00701-025-06562-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。